Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Michael H. Davidson to C-Reactive Protein

This is a "connection" page, showing publications Michael H. Davidson has written about C-Reactive Protein.

 
Connection Strength
 
 
 
1.094
 
  1. Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. Lipids Health Dis. 2015 Sep 02; 14:98.
    View in: PubMed
    Score: 0.137
  2. Mangalmurti SS, Davidson MH. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. Curr Atheroscler Rep. 2011 Oct; 13(5):373-80.
    View in: PubMed
    Score: 0.104
  3. Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
    View in: PubMed
    Score: 0.102
  4. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
    View in: PubMed
    Score: 0.099
  5. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct; 5(10):621-35.
    View in: PubMed
    Score: 0.084
  6. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
    View in: PubMed
    Score: 0.083
  7. Polonsky TS, Davidson MH. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.082
  8. Davidson MH. Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
    View in: PubMed
    Score: 0.075
  9. Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther. 2006 Jul; 4(4):461-76.
    View in: PubMed
    Score: 0.072
  10. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006 Apr 15; 97(8):1198-205.
    View in: PubMed
    Score: 0.071
  11. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005 Aug 30; 112(9):1289-95.
    View in: PubMed
    Score: 0.068
  12. Rubicz R, Zhu J, Laston S, Cole SA, Voruganti VS, Ebbesson SO, Howard BV, Maccluer JW, Davidson M, Umans JG, Comuzzie AG, Göring HH. Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study. Genet Epidemiol. 2013 Nov; 37(7):751-7.
    View in: PubMed
    Score: 0.029
  13. Friedewald VE, Ballantyne CM, Davidson MH, Gotto AM, Ridker PM, Roberts WC. The editor's roundtable: JUPITER follow-up. Am J Cardiol. 2011 May 15; 107(10):1549-57.
    View in: PubMed
    Score: 0.025
  14. Ridker PM, Friedewald VE, Davidson MH, Willerson JT, Roberts WC. The editor's roundtable: the JUPITER trial--initial results and clinical implications. Am J Cardiol. 2009 May 15; 103(10):1417-25.
    View in: PubMed
    Score: 0.022
  15. Sam S, Haffner S, Davidson MH, D'Agostino RB, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009 May; 32(5):932-7.
    View in: PubMed
    Score: 0.022
  16. Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther. 2006 Jun; 28(6):849-59.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.